PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Strontium Radioisotopes”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5Linked to original sources
PubMed1978

Microlocalization of artificial radionuclides in radiological protection of the environment.

Though environmental biological equilibrium seems to be safeguarded as long as the radiological protection of man is assumed, a number of problems raised by environmental protection are not fully solved. In particular, there occur both macroscopic processes of concentration at some levels of the biological chains, and microlocalization at the cellular, subcellular and molecular levels. The long-term consequences of the non-uniform distribution of the radionuclides should therefore be assessed even if the contamination levels of the physical environment are very low. These aspects are of particular significance with alpha-emitters (plutonium and transplutonium elements), beta-emitters (chiefly tritium) and activation products, some of which are radioisotopes of biologically significant elements. The incidence of these processes is discussed in the light of recent and future developments in nuclear energy. This approach might open new avenues for investigations in environmental radiological protection. The concept of a concentration factor between the environment and the total organism must be supplemented by the concept of a localization and concentration factor at the subcellular level. The significance of the physico-chemical forms of the radionuclides and the parameters likely to modify the characteristics of membranes should be emphasized. Finally, an indication is given on priority measures in the area of investigations of the long-term consequences of low doses on environmental organisms.

Animals↗
PubMed1996

Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89.

Strontium-89 (89Sr) is currently used for the treatment of painful bone metastases. This study reports the use of low-dose carboplatin as a radiosensitizer in 89Sr radioisotope therapy. The study design comprised two groups: 15 patients treated with 89Sr (148 MBq) followed by carboplatin (100 mg m-2 at 7 and 21 days) and 15 patients treated with 89Sr alone. Their pain response was assessed 8 weeks post-injection. Follow-up was continued for up to 1 year in the survivors. Twenty-seven patients were evaluable. A pain response was observed in 20 of 27 (74%) patients. The pain response in the patients treated with 89Sr and carboplatin was clearly superior to that seen in the patients treated with 89Sr alone (P = 0.025), whereas survival was only marginally better in the combined treatment group (8.1 vs 5.7 months, P = 0.19). No clinically significant adverse effects or myelosuppression by carboplatin were observed. Low-dose carboplatin enhances the effects of 89Sr radioisotope therapy on pain from bone metastases.

Adult↗